[Read more: Mayne Pharma, Mithra Pharmaceuticals debut Nextstellis ] Nuvaring brand generic sales were approximately $580 million for the 12 months ending June 2022, according to IQVIA. Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra Pharmaceuticals 6 million euro as a result of receiving FDA approval and 1.6 million euro upon commercial launch in the United States. Mithra will manufacture Haloette at its contract development and manufacturing organization facility in Belgium. "We are very pleased to announce the approval of Haloette in the U.S. and look forward to bringing this drug-device generic to market, " Mayne Pharma's CEO Scott Richards said. "Mayne Pharma is proudly committed to providing women with more affordable and accessible contraceptive choices.